$MLRT
Metalert, Inc. Stock $mlrt

$mlrt Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223042386 Filed on November 22, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$41.06K	$85.74K	$67.65K
YoY Change	20.62%	26.74%	-55.36%
Cost Of Revenue	$67.55K	$85.66K	$26.35K
YoY Change	154.04%	225.11%	-61.33%
Gross Profit	-$26.49K	$77.00	$41.31K
YoY Change	-455.57%	-99.81%	-50.49%
Gross Profit Margin	-64.52%	0.09%	61.05%
Selling, General & Admin	$228.7K	$70.60K	$71.76K
YoY Change	-66.9%	-1.62%	-4.42%
% of Gross Profit		91693.51%	173.74%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$26.04K	$8.340K
YoY Change	-21.9%
% of Gross Profit		10831.17%
Operating Expenses	$237.1K	$253.5K	$281.5K
YoY Change	-66.1%	-9.95%	0.85%
Operating Profit	-$263.5K	-$253.4K	-$240.2K
YoY Change	-61.91%	5.5%	22.73%
Interest Expense	-$830.00	-$155.2K
YoY Change	-98.5%
% of Operating Profit
Other Income/Expense, Net	-$39.69K	-$176.2K	-$62.28K
YoY Change	-60.64%	182.86%	279.04%
Pretax Income	-$302.9K	-$429.6K
YoY Change	-61.17%
Income Tax
% Of Pretax Income
Net Earnings	-$302.9K	-$429.6K	-$302.5K
YoY Change	-61.17%	42.02%	42.58%
Net Earnings / Revenue	-737.63%	-501.0%	-447.08%
Basic Earnings Per Share		-$0.02	-$0.06
Diluted Earnings Per Share	-$0.01	-$0.02	-$0.06
COMMON SHARES
Basic Shares Outstanding	32.12M shares	23.52M shares	247.1M shares
Diluted Shares Outstanding		25.84M shares	5.066M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$69.09K	$107.0K
YoY Change	649.35%
Cash & Equivalents	$68.44K	$106.3K	$24.00K
Short-Term Investments	$650.00	$650.00
Other Short-Term Assets	$4.339K	$4.769K	$17.83K
YoY Change	-46.07%	-73.25%	-87.83%
Inventory	$231.8K	$256.6K	$91.00K
Prepaid Expenses
Receivables	$17.41K	$62.14K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$322.7K	$430.5K	$157.2K
YoY Change	218.41%	173.79%	-73.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.78K	$34.12K	$67.46K
YoY Change	-56.39%	-49.43%	3.34%
Goodwill
YoY Change
Intangibles	$261.8K	$279.5K	$3.308K
YoY Change	7812.97%	8348.16%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$287.5K	$313.6K	$70.76K
YoY Change	360.59%	343.13%	8.41%
TOTAL ASSETS
Total Short-Term Assets	$322.7K	$430.5K	$157.2K
Total Long-Term Assets	$287.5K	$313.6K	$70.76K
Total Assets	$610.2K	$744.1K	$228.0K
YoY Change	272.61%	226.35%	-65.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$264.7K	$205.9K	$127.2K
YoY Change	92.75%	61.87%	-7.05%
Accrued Expenses	$327.3K	$277.0K	$334.1K
YoY Change	-15.72%	-17.08%	16.44%
Deferred Revenue	$6.505K	$6.450K	$15.98K
YoY Change	-49.38%	-59.62%	-48.43%
Short-Term Debt	$2.896M	$2.805M
YoY Change	31.12%
Long-Term Debt Due	$115.0K	$111.2K
YoY Change	28.43%
Total Short-Term Liabilities	$4.372M	$4.161M	$3.179M
YoY Change	31.11%	30.91%	5.37%
LONG-TERM LIABILITIES
Long-Term Debt	$137.0K	$138.3K
YoY Change	-3.57%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$137.0K	$138.3K
YoY Change	-3.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.372M	$4.161M	$3.179M
Total Long-Term Liabilities	$137.0K	$138.3K
Total Liabilities	$4.509M	$4.300M	$3.322M
YoY Change	29.7%	29.43%	2.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.75M	-$28.44M	-$26.78M
YoY Change	4.32%	6.23%	4.55%
Common Stock	$3.245K	$3.187K	$1.556K
YoY Change	88.88%	104.82%	-92.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.899M	-$3.555M	-$3.094M
YoY Change
Total Liabilities & Shareholders Equity	$610.2K	$744.1K	$228.0K
YoY Change	272.61%	226.35%	-65.71%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$302.9K	-$429.6K	-$302.5K
YoY Change	-61.17%	42.02%	42.58%
Depreciation, Depletion And Amortization	$26.04K	$8.340K
YoY Change	-21.9%
Cash From Operating Activities	-$122.1K	-$139.4K
YoY Change	-75.92%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$42.41K
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$42.41K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	84.18K	158.2K
YoY Change	-77.87%
NET CHANGE
Cash From Operating Activities	-122.1K	-139.4K
Cash From Investing Activities	0.000	42.41K
Cash From Financing Activities	84.18K	158.2K
Net Change In Cash	-37.90K	61.24K
YoY Change	-70.8%
FREE CASH FLOW
Cash From Operating Activities	-$122.1K	-$139.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001375793
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2023Q3	MLRT	Grant From Care Loans GrantFromCareLoans		usd
CY2022Q3	MLRT	Grant From Care Loans GrantFromCareLoans		usd
	MLRT	Grant From Care Loans GrantFromCareLoans		usd
CY2023Q3	MLRT	Edd Recovery Due To Covid EddRecoveryDueToCovid		usd
CY2022Q3	MLRT	Edd Recovery Due To Covid EddRecoveryDueToCovid		usd
	MLRT	Edd Recovery Due To Covid EddRecoveryDueToCovid		usd
CY2022Q3	MLRT	Stock Returned During Period Value Preferred A Stock To Treasury StockReturnedDuringPeriodValuePreferredAStockToTreasury		usd
	MLRT	Stock Returned During Period Value Preferred A Stock To Treasury StockReturnedDuringPeriodValuePreferredAStockToTreasury		usd
	MLRT	Grant From Care Loans GrantFromCareLoans		usd
	MLRT	Gains Losses On Settlement Of Debt And Accrued Interest GainsLossesOnSettlementOfDebtAndAccruedInterest		usd
	MLRT	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Increase Decrease In Due To Officers And Stockholders Current IncreaseDecreaseInDueToOfficersAndStockholdersCurrent		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	MLRT	Debt Discount On Convertible Notes DebtDiscountOnConvertibleNotes		usd
	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent		usd
CY2023Q3	MLRT	Paycheck Protection Program Loan Amount PaycheckProtectionProgramLoanAmount		usd
CY2022Q4	MLRT	Paycheck Protection Program Loan Amount PaycheckProtectionProgramLoanAmount		usd
	MLRT	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-53046
	dei	Entity Registrant Name EntityRegistrantName	MetAlert, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0493446
	dei	Entity Address Address Line1 EntityAddressAddressLine1	117 W. 9th Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1214
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90015
	dei	City Area Code CityAreaCode	(213)
	dei	Local Phone Number LocalPhoneNumber	489-3019
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.0001
	dei	Trading Symbol TradingSymbol	MLRT
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32120931	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106333	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8534	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	62137	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	13959	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	256632	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	70112	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	649	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	683	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4769	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8045	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	430520	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	101333	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	279465	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3308	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34115	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59121	usd
CY2023Q3	us-gaap	Assets Assets	744100	usd
CY2022Q4	us-gaap	Assets Assets	163762	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	205936	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	137315	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	277045	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	388414	usd
CY2023Q3	MLRT	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	755259	usd
CY2022Q4	MLRT	Accrued Expenses Related Parties Current AccruedExpensesRelatedPartiesCurrent	497551	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6450	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12850	usd
CY2023Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	99511	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	81651	usd
CY2023Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	11694	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	7903	usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1423696	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	843000	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	146195	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	149120	usd
CY2023Q3	MLRT	Notes Payable Related Parties NotesPayableRelatedParties	40800	usd
CY2022Q4	MLRT	Notes Payable Related Parties NotesPayableRelatedParties	10000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4161221	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3334542	usd
CY2023Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	138306	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	142097	usd
CY2023Q3	us-gaap	Liabilities Liabilities	4299527	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3476639	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2071000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2071000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31870931	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31870931	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17179794	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17179794	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	3187	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1718	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24885133	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24241862	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28443763	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27556471	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3555427	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3312877	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	744100	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	163762	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	85741	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	67653	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	207272	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	300570	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	85664	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	26349	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	159344	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	163173	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	77	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	41305	usd
	us-gaap	Gross Profit GrossProfit	47928	usd
	us-gaap	Gross Profit GrossProfit	137397	usd
CY2023Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	120865	usd
CY2022Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	127829	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	363359	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	382916	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	61995	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	81893	usd
	us-gaap	Professional Fees ProfessionalFees	113917	usd
	us-gaap	Professional Fees ProfessionalFees	257232	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5372	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3494	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5352	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19092	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	65232	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	68269	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	178690	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	156670	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	253464	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	281485	usd
	us-gaap	Operating Expenses OperatingExpenses	661318	usd
	us-gaap	Operating Expenses OperatingExpenses	815911	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-253387	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-240180	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-613390	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-678514	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	44217	usd
CY2022Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-94	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-34	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-1369	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	21028	usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	16526	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	63247	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	29089	usd
	MLRT	Grant From Care Loans GrantFromCareLoans	67870	usd
	MLRT	Edd Recovery Due To Covid EddRecoveryDueToCovid	34191	usd
CY2023Q3	MLRT	Interest Expense Income And Financing Costs InterestExpenseIncomeAndFinancingCosts	-155146	usd
CY2022Q3	MLRT	Interest Expense Income And Financing Costs InterestExpenseIncomeAndFinancingCosts	-45663	usd
	MLRT	Interest Expense Income And Financing Costs InterestExpenseIncomeAndFinancingCosts	-254836	usd
	MLRT	Interest Expense Income And Financing Costs InterestExpenseIncomeAndFinancingCosts	-116161	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-176174	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-62283	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-273901	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-44558	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-429561	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-302463	usd
	us-gaap	Net Income Loss NetIncomeLoss	-887291	usd
	us-gaap	Net Income Loss NetIncomeLoss	-723072	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-429561	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-302463	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-887291	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-723072	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25838157	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25838157	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5066220	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5066220	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23348693	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23348693	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4161828	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4161828	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3708292	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	22780	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	11896	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	347900	usd
CY2023Q3	MLRT	Issuance Of Preferred Stock For Financings IssuanceOfPreferredStockForFinancings	100000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	99850	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-429561	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3555427	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3054530	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	57109	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	114062	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30492	usd
CY2022Q3	MLRT	Issuance Of Common Stock For Conversion Of Warrants IssuanceOfCommonStockForConversionOfWarrants	985	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	60349	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-302463	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3093995	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3312877	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	22780	usd
	MLRT	Issuance Of Preferred Stock For Financings IssuanceOfPreferredStockForFinancings	100000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	99850	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	74211	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	347900	usd
	us-gaap	Net Income Loss NetIncomeLoss	-887291	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3555427	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2879621	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2879621	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	129286	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	180000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	114062	usd
	MLRT	Issuance Of Common Stock For Conversion Of Warrants IssuanceOfCommonStockForConversionOfWarrants	25000	usd
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	60349	usd
	us-gaap	Net Income Loss NetIncomeLoss	-723072	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3093995	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3093995	usd
	us-gaap	Net Income Loss NetIncomeLoss	-887291	usd
	us-gaap	Net Income Loss NetIncomeLoss	-723072	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25005	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25005	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-34	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	106333	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23998	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-1369	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	22780	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	129286	usd
	MLRT	Grant From Care Loans GrantFromCareLoans	67870	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	63247	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	29089	usd
	MLRT	Gains Losses On Settlement Of Debt And Accrued Interest GainsLossesOnSettlementOfDebtAndAccruedInterest	-27537	usd
	MLRT	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	-16680	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	99850	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	48177	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9592	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-42815	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7261	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3275	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-37189	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	194450	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-33563	usd
	MLRT	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	171456	usd
	MLRT	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	82698	usd
	MLRT	Increase Decrease In Account Payable And Financing Costs IncreaseDecreaseInAccountPayableAndFinancingCosts	-50877	usd
	MLRT	Increase Decrease In Account Payable And Financing Costs IncreaseDecreaseInAccountPayableAndFinancingCosts	116641	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6400	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-21275	usd
	us-gaap	Increase Decrease In Due To Officers And Stockholders Current IncreaseDecreaseInDueToOfficersAndStockholdersCurrent	30450	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-295166	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-426835	usd
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	-42408	usd
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	3308	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42408	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3308	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	46881	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	69180	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	180000	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	145000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	25000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	275000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	100000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	29021	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	59180	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	42304	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	44201	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	350556	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	315799	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	97798	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-114345	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8535	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	138342	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	74211	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	114062	usd
	MLRT	Debt Discount On Convertible Notes DebtDiscountOnConvertibleNotes	17150	usd
	us-gaap	Stock Issued1 StockIssued1	22780	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3555427	usd
CY2023Q3	MLRT	Working Capital WorkingCapital	3730701	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	207272	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	300570	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	207272	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	300570	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	12431	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	12431	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	51531	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	213280	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	18581	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	256632	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	70112	usd
	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The Company’s warranty policy provides repair or replacement of products (excluding GPS Shoe devices) returned for defects within ninety days of purchase
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zCguT7z3zyo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86B_zSQ4EYARXFEl">Use of Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the accompanying unaudited financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, estimates related to revenue recognition, allowance for doubtful accounts, inventory valuation, tangible and intangible long-term asset valuation, warranty and other obligations and commitments. Estimates are updated on an ongoing basis and are evaluated based on historical experience and current circumstances. Changes in facts and circumstances in the future may give rise to changes in these estimates which may cause actual results to differ from current estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zWhBHQKgJvib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86C_zTz4vjfpaP1j">Concentrations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently rely on one manufacturer to supply us with our GPS SmartSole and one manufacturer to supply us with the GPS device included in the GPS SmartSole. The loss of either of these manufacturers could severely impede our ability to manufacture the GPS SmartSole.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, the Company had four customers representing approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8RxkBBHwxkj">26</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zOUSdfnKwog2">19</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zNAig7zLf9Ca">19</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zid88k77O6J7">14</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of sales, respectively, and four customers representing approximately <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zMD8X48F72S7">39</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zuwDK3cZ7Ece">22</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zUqdifBO3Iec">19</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zfhm4aDhvHVa">6</span>% of total accounts receivable, respectively. As of September 30, 2022, the Company had five customers representing approximately </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpP8sQGgLHb1">28</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z9PSJYMhZKmh">23</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zmS9ALuY2HFe">16</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zz3ijOLAgfQ2">6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerFiveMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zQyMuDOP0Iqh">6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of sales, respectively (</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskCustomer_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZNmwiap7tKk">34% in receivables represents sales made through our online stores and consists of approximately 2,000 different customers</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">), and five customers representing approximately </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zvYyzp7Eugqg">25</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zgGoDcVOczs3">18</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zjmr5lVfEgI2">18</span>%</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerFourMember_zH8jF7W3X4S9">12</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerFiveMember_zmNFJbSQWhC">8</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of total accounts receivable, respectively (excluding related party payables).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	649	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	683	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	105989623	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	174889151	shares
	MLRT	Investment Owned Description InvestmentOwnedDescription	The Company’s investments in marketable securities is comprised of shares of stock of two (2) entities with ownership percentages of less than 5%. The Company accounted for these investments pursuant to ASU 320, Investments – Debt and Equity Securities. As such, these investments were recorded at their market value as of December 31, 2019, with the change in fair value being reflected in the statement of operations
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	43352	usd
	MLRT	Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Convertible Notes BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToConvertibleNotes	200000	usd
	MLRT	Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Common Stock BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCommonStock	347900	usd
	us-gaap	Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1 BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1	547900	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	42408	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	229335	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	547900	usd
CY2023Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	85741	usd
CY2022Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	67653	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	207272	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	300570	usd
CY2023Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-485309	usd
CY2022Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-417593	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-1156318	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-1166832	usd
CY2023Q3	us-gaap	Line Of Credit LineOfCredit	99511	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	7903	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	479919	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	454913	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34115	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59121	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	279465	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3308	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	146195	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	149120	usd
CY2023Q3	us-gaap	Other Borrowings OtherBorrowings	11694	usd
CY2022Q4	us-gaap	Other Borrowings OtherBorrowings	81651	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	257400	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	238674	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1051176	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	843000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	17150	usd
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt	1423696	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	843000	usd
CY2023Q3	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	11694	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	7903	usd
CY2023Q3	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	138306	usd
CY2022Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	142097	usd
CY2023Q3	MLRT	Short Term And Long Term Loans Payable ShortTermAndLongTermLoansPayable	150000	usd
CY2022Q4	MLRT	Short Term And Long Term Loans Payable ShortTermAndLongTermLoansPayable	150000	usd
CY2022Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	68870	usd
CY2021	MLRT	Due To Related Parties Amount Converted Into Notes DueToRelatedPartiesAmountConvertedIntoNotes	200000	usd
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	459692	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	129286	usd
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-65 reverse stock split
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	603846	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	400000	shares
	MLRT	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice	0.975
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	157692	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	846154	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	846154	shares
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	25552	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	75308	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q3	MLRT	Bonus Declared Or Accrued BonusDeclaredOrAccrued	0	usd
CY2022Q4	MLRT	Bonus Declared Or Accrued BonusDeclaredOrAccrued	0	usd

Files In Submission

Name	View Source	Status
mlrt-20230930_def.xml	Edgar Link	unprocessable
0001493152-23-042386-index-headers.html	Edgar Link	pending
0001493152-23-042386-index.html	Edgar Link	pending
0001493152-23-042386.txt	Edgar Link	pending
0001493152-23-042386-xbrl.zip	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
ex3-1_001.jpg	Edgar Link	pending
ex3-1_002.jpg	Edgar Link	pending
ex3-1_003.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
mlrt-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
mlrt-20230930_lab.xml	Edgar Link	unprocessable
mlrt-20230930_cal.xml	Edgar Link	unprocessable
mlrt-20230930_pre.xml	Edgar Link	unprocessable
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MLRT
Metalert, Inc. Stock $mlrt

2023 Q4 Form 10-Q Financial Statement

#000149315223042386 Filed on November 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLRT Metalert, Inc. Stock $mlrt

2023 Q4 Form 10-Q Financial Statement

#000149315223042386 Filed on November 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLRT
Metalert, Inc. Stock $mlrt